The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Rivastigmine for Alzheimer's disease
Abstract
BACKGROUND: Alzheimer's disease (AD) is the commonest cause of dementia affecting older people. One of the therapeutic strategies aimed at ameliorating the clinical manifestations of Alzheimer's disease is to enhance cholinergic neurotransmission in relevant parts of the brain by the use of cholinesterase inhibitors to delay the breakdown of acetylcholine released into synaptic clefts. Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity. Other cholinesterase inhibitors, including rivastigmine, with superior properties in terms of specificity of action and low risk of adverse effects, have now been introduced. Rivastigmine has received approval for use in 60 countries including all member states of the European Union and the USA. OBJECTIVES: To determine the clinical efficacy and safety of rivastigmine for patients with dementia of Alzheimer's type. SEARCH STRATEGY: The Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (CDCIG), The Cochrane Library, MEDLINE, EMBASE, PsycINFO, CINAHL and LILACS were searched on 27 March 2008 using the terms: Rivastigmine OR exelon OR ENA OR "SDZ ENA 713" . The CDCIG Specialized Register contains records from all major health care databases (The Cochrane Library, MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS) as well as from many clinical trials registries and grey literature sources. SELECTION CRITERIA: All unconfounded, double-blind, randomized trials in which treatment with rivastigmine was administered to patients with dementia of the Alzheimer's type for more than two weeks and its effects compared with those of placebo in a parallel group of patients. DATA COLLECTION AND ANALYSIS: One reviewer (JSB) applied study selection criteria, assessed the quality of studies and extracted data. MAIN RESULTS: Nine trials, involving 4775 participants, were included in the analyses. Use of rivastigmine in high doses was associated with statistically significant benefits on several measures. High-dose rivastigmine (6 to 12 mg daily) was associated with a two-point improvement in cognitive function on the ADAS-Cog score compared with placebo (weighted mean difference -1.99, 95% confidence interval -2.49 to -1.50, on an intention-to-treat basis) and a 2.2 point improvement in activities of daily living assessed on the Progressive Deterioration Scale (weighted mean difference -2.15, 95% confidence interval -3.16 to -1.13, on an intention-to-treat basis) at 26 weeks. At lower doses (4 mg daily or lower) differences were in the same direction but were statistically significant only for cognitive function. There were statistically significantly higher numbers of events of nausea, vomiting, diarrhoea, anorexia, headache, syncope, abdominal pain and dizziness among patients taking high-dose rivastigmine than among those taking placebo. There was some evidence that adverse events might be less common with more frequent, smaller doses of rivastigmine. The 2008 update includes a new study testing two types of rivastigmine transdermal patch, one delivering a higher dose than previously tested (17.4 mg/day) and a smaller patch delivering 9.6 mg/day. The efficacy of the smaller patch was not significantly different compared with the capsules of similar daily dose, but was associated with significantly fewer adverse events of nausea, vomiting, dizziness and asthenia. The efficacy of the larger patch was not significantly different compared with the smaller patch, but the smaller patch was associated with significantly fewer adverse events of nausea, vomiting, weight loss and dizziness. There appears to be advantages associated with the smaller patch compared with both the higher dose patch and the 6-12 mg/day capsules. AUTHORS' CONCLUSIONS: Rivastigmine appears to be beneficial for people with mild to moderate Alzheimer's disease. In comparisons with placebo, improvements were seen in the rate of decline of cognitive function, activities of daily living, and severity of dementia with daily doses of 6 to 12 mg. Adverse events were consistent with the cholinergic actions of the drug. A transdermal patch has been tested in one trial, and there is evidence that the lower dose smaller patch is associated with fewer side effects than the capsules or the higher dose larger patch and has comparable efficacy to both. This review has not examined economic data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
(1976) · Medical Entomology and Zoology · Cited by 8,899
Validity of the Trail Making Test as an Indicator of Organic Brain Damage
Reitan, R. M. (1958) · Perceptual and Motor Skills · doi:10.2466/pms.1958.8.3.271 · Cited by 7,928
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
The Global Deterioration Scale for assessment of primary degenerative dementia
(1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.9.1136 · Cited by 4,986
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
Bias in treatment assignment in controlled clinical trials
Chalmers, T. C., Celano, P., Sacks, H. S., & Smith, H. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312013092204 · Cited by 864
Schneider, L. S., Olin, J. T., Doody, R. S., Clark, C. M., Morris, J. C., Reisberg, B., Schmitt, F. A., Grundman, M., Thomas, R. G., & Ferris, S. H. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00004 · Cited by 647
Corey-Bloom, J. (1998) · Medical Entomology and Zoology · Cited by 467
Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease:
Grossberg, G. T. (2003) · Current Therapeutic Research · doi:10.1016/s0011-393x(03)00059-6 · Cited by 384
Clock Completion: An Objective Screening Test for Dementia
Watson, Y. I., Arfken, C. L., & Birge, S. J. (1993) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1993.tb07308.x · Cited by 339
Severe Impairment Battery: A Neuropsychological Test for Severely Demented Patients
Panisset, M. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540130067012 · Cited by 323
Polinsky, R. J. (1998) · Clinical Therapeutics · doi:10.1016/s0149-2918(98)80127-6 · Cited by 323
Ballard, C., Margallo-Lana, M., Juszczak, E., Douglas, S., Swann, A., Thomas, A., O'Brien, J., Everratt, A., Sadler, S., Maddison, C., et al. (2005) · BMJ · doi:10.1136/bmj.38369.459988.8f · Cited by 315
Winblad, B., Cummings, J., Andreasen, N., Grossberg, G., Onofrj, M., Sadowsky, C., Zechner, S., Nagel, J., & Lane, R. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1788 · Cited by 286
Donepezil for dementia due to Alzheimer's disease
Birks, J., & Harvey, R. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub2 · Cited by 285
Self-citationRivastigmine, a New‐Generation Cholinesterase Inhibitor for the Treatment of Alzheimer's Disease
Jann, M. W. (2000) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.1.1.34664 · Cited by 236
Bullock, R., Touchon, J., Bergman, H., Gambina, G., He, Y., Rapatz, G., Nagel, J., & Lane, R. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x56565 · Cited by 228
Behavioral symptoms in mild cognitive impairment
Feldman, H., Scheltens, P., Scarpini, E., Hermann, N., Mesenbrink, P., Mancione, L., Tekin, S., Lane, R., & Ferris, S. (2004) · Neurology · doi:10.1212/01.wnl.0000118301.92105.ee · Cited by 219
Saxton, J., McGonigle-Gibson, K. L., Swihart, A. A., & Miller, V. J. (1990) · Psychological Assessment · doi:10.1037//1040-3590.2.3.298 · Cited by 195
Rivastigmine: A Review of its Use in Alzheimer??s Disease
Spencer, C. M., & Noble, S. (1998) · Drugs & Aging · doi:10.2165/00002512-199813050-00005 · Cited by 187
Measurement of quality-of-life changes in patients with Alzheimer's disease.
Dejong, R. N., Osterlund, O. W., & Roy, G. W. (1989) · PubMed · Cited by 186
Ritchie, C. W., Ames, D., Clayton, T., & Lai, R. (2004) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200407000-00003 · Cited by 179
Kumar, V., Anand, R., Messina, J., Hartman, R., & Veach, J. (2000) · European Journal of Neurology · doi:10.1046/j.1468-1331.2000.00046.x · Cited by 159
Rivastigmine for Alzheimer's disease
Birks, J., Grimley Evans, J., Iakovidou, V., & Tsolaki, M. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191 · Cited by 159
Self-citationWilkinson, D., Passmore, A., Bullock, R., Hopker, S., Smith, R., Potocnik, F., Maud, C., Engelbrecht, I., Hock, C., Ieni, Jr., et al. (2002) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2002.tb11294.x · Cited by 158
Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease
Potkin, S. G., Anand, R., Fleming, K., Alva, G., Keator, D., Carreon, D., Messina, J., Wu, J. C., Hartman, R., & Fallon, J. H. (2001) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145701002528 · Cited by 158
Winblad, B., Grossberg, G., Frölich, L., Farlow, M., Zechner, S., Nagel, J., & Lane, R. (2007) · Neurology · doi:10.1212/01.wnl.0000281847.17519.e0 · Cited by 136
Fuld, P. A. (1977) · PsycTESTS Dataset · doi:10.1037/t06066-000 · Cited by 125
Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease
Cutler, N. R., Polinsky, R. J., Srarnek, J. J., Enz, A., Jhee, S. S., Mancione, L., Hourani, J., & Zolnouni, P. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1998.tb00645.x · Cited by 124
A review of rivastigmine: A reversible cholinesterase inhibitor
Williams, B. R., Nazarians, A., & Gill, M. A. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80160-1 · Cited by 122
Auriacombe, S., Péré, J.-J., Loria-Kanza, Y., & Vellas, B. J. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125000471 · Cited by 118
Mowla, A., Mosavinasab, M., Haghshenas, H., & Haghighi, A. B. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31814b98c1 · Cited by 116
Rösler, M., Retz, W., Retz‐Junginger, P., & Dennler, H. J. (1999) · Behavioural Neurology · doi:10.1155/1999/168023 · Cited by 112
Feldman, H., Lane, R. M., & on behalf of the Study 304 Group (2007) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.099424 · Cited by 110
DANTOINE, T. F., Auriacombe, S., Sarazin, M., Becker, H., Pere, J.-J., & Bourdeix, I. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00769.x · Cited by 108
Winblad, B. G., Kawata, A. K., Beusterien, K. M., Thomas, S. K., Wimo, A. B., Lane, R. M., Fillit, H. M., & Blesa, R. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1806 · Cited by 101
Forette, F., Anand, R., & Gharabawi, G. (1999) · European Journal of Neurology · doi:10.1046/j.1468-1331.1999.640423.x · Cited by 99
Farlow, M. R., Hake, A. M., Messina, J. C., Hartman, R. D., Veach, J., & Anand, R. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.417 · Cited by 98
Grossberg, G. T., Stähelin, H. B., Messina, J. C., Anand, R., & Veach, J. (2000) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(200003)15:3<242::aid-gps110>3.0.co;2-7 · Cited by 94
Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years
Small, G. W., Kaufer, D., Mendiondo, M. S., Quarg, P., & Spiegel, R. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00524.x · Cited by 91
Thomas, A., Iacono, D., Bonanni, L., D’Andreamatteo, G., & ONOFRJ, M. C. (2001) · Clinical Neuropharmacology · doi:10.1097/00002826-200101000-00007 · Cited by 86
Farlow, M. R., Potkin, S. G., Koumaras, B., Veach, J., & Mirski, D. F. (2003) · Archives of Neurology · doi:10.1001/archneur.60.6.843 · Cited by 76
Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease
Blesa, R., Ballard, C. G., Orgogozo, J., Lane, R. M., & Thomas, S. K. (2007) · Neurology · doi:10.1212/01.wnl.0000281848.25142.11 · Cited by 76
CLINICAL AND COST-EFFECTIVENESS OF DONEPEZIL, RIVASTIGMINE, AND GALANTAMINE FOR ALZHEIMER'S DISEASE
Clegg, A. J., Bryant, J., Nicholson, T., McIntyre, L., Broe, S. D., Gerard, K., & Waugh, N. R. (2002) · International Journal of Technology Assessment in Health Care · doi:10.1017/s026646230200034x · Cited by 76
Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease
Sramek, J. J., Anand, R., Wardle, T. S., Irwin, P., Hartman, R. D., & Cutler, N. R. (1996) · Life Sciences · doi:10.1016/0024-3205(96)00081-1 · Cited by 75
Preferential Cerebrospinal Fluid Acetylcholinesterase Inhibition by Rivastigmine in Humans
Kennedy, J. S., Polinsky, R. J., Johnson, B. W., Loosen, P. T., Enz, A., Laplanche, R., Schmidt, D. E., Mancione, L., Parris, W. C. V., & Ebert, M. H. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199912000-00005 · Cited by 74
Karaman, Y., Erdoğan, F. F., Köseoğlu, E., Turan, T., & Ersoy, A. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000080972 · Cited by 72
Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease
Burns, A. S., Spiegel, R., & Quarg, P. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1058 · Cited by 71
Brassen, S., & Adler, G. (2003) · Pharmacopsychiatry · doi:10.1055/s-2003-45118 · Cited by 69
Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease
Bullock, R. A., Bergman, H., Touchon, J., Gambina, G., He, Y., Nagel, J., & Lane, R. M. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x89685 · Cited by 67
Blesa, R., Bullock, R. A., He, Y., Bergman, H., Gambina, G., Meyer, J. M., Rapatz, G., Nagel, J., & Lane, R. M. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000220573.05714.ac · Cited by 65
Hauber, B., Gnanasakthy, A., & Mauskopf, J. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)89012-8 · Cited by 65
Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type
Agid, Y., Dubois, B., Anand, R., & Gharabawi, G. (1998) · Current Therapeutic Research · doi:10.1016/s0011-393x(98)85048-0 · Cited by 64
Hossain, M. S., Jhee, S. S., Shiovitz, T. M., McDonald, C., Sedek, G., Pommier, F., & Cutler, N. R. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241030-00006 · Cited by 60
Touchon, J., Bergman, H., Bullock, R. A., Rapatz, G., Nagel, J., & Lane, R. M. (2005) · Current Medical Research and Opinion · doi:10.1185/030079906x80279 · Cited by 59
Aupperle, P. M., Koumaras, B., Chen, M. J., Rabinowicz, A. L., & Mirski, D. F. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004204 · Cited by 59
Almkvist, O., Darreh‐Shori, T., Stefanova, E. D., Spiegel, R., & Nordberg, A. K. (2004) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00757.x · Cited by 58
A rivastigmine patch for the treatment of Alzheimer’s disease and Parkinson’s disease dementia
Cummings, J. L., & Winblad, B. G. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.11.1457 · Cited by 50
Electrocardiographic Effects of Rivastigmine
Morganroth, J., Graham, S. M., Hartman, R. D., & Anand, R. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/00912700222011490 · Cited by 49
Weiser, M., Rotmensch, H. H., Korczyn, A. D., Hartman, R. D., Cicin-Sain, A., & Anand, R. (2002) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.599 · Cited by 46
Marin, D. B., Amaya, K., Casciano, R., Puder, K. L., Casciano, J., Cuccia, A. J., Chang, S., Snyder, E. H., & Cheng, I. (2003) · International Psychogeriatrics · doi:10.1017/s1041610203009633 · Cited by 43
RIVASTIGMINE IN PATIENTS WITH ALZHEIMER'S DISEASE AND CONCURRENT HYPERTENSION
Erkinjuntti, T., Skoog, I. G., Lane, R. M., & Andrews, C. (2002) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2002.tb11377.x · Cited by 39
Erkinjuntti, T., Skoog, I. G., Lane, R. M., & Andrews, C. (2003) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2003.tb10609.x · Cited by 31
Fillit, H. M., & Hill, J. W. (2004) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000127492.65032.d3 · Cited by 28
Holmes, C., Wilkinson, D. G., Dean, C., Clare, C., El‐Okl, M., Hensford, C., & Moghul, S. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1667 · Cited by 28
Identification of responders and reactive domains to rivastigmine in Alzheimer's disease
Frankfort, S. V., Appels, B. A., de Boer, A., Tulner, L. R., van Campen, J. P. C. M., Koks, C. H. W., Beijnen, J. H., & Schmand, B. A. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1345 · Cited by 26
Rivastigmine in outpatient services: experience of 114 neurologists in Austria
Schmidt, R., Lechner, A., & Petrovic, K. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200203000-00007 · Cited by 24
Cognitive deficits in Alzheimer's disease: Treatment with acetylcholinesterase inhibitor agents
Fuschillo, C., Pia, S. L., Campana, F., Pinto, A. V., & Simone, L. D. (2001) · Archives of Gerontology and Geriatrics · doi:10.1016/s0167-4943(01)00134-0 · Cited by 23
Rivastigmine in Alzheimer Disease: Efficacy Over Two Years
Grossberg, G. T. (2004) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.12.4.420 · Cited by 21
Bilikiewicz, A., Opala, G., Podemski, R., Puźyński, S., Łapin, J., Sołtys, K., Ochudlo, S., Barcikowska, M., Pfeffer, A., Bilińska, M. M., et al. (2002) · PubMed · Cited by 17
Birks, J. (2007) · International Psychogeriatrics · doi:10.1017/s1041610207006977 · Cited by 11
Self-citationCaffarra, P., Vezzadini, G., Copelli, S., Dieci, F., Messa, G., Nonis, E., & Venneri, A. (2007) · PubMed · Cited by 10
Auriacombe, S., & Péré, J.-J. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125002504 · Cited by 9
Hock, C., Wilkinson, D. G., Passmore, P., Bullock, R. M., Hopker, S. W., Smith, R. A., Potocnik, F. C. V., Maud, C., Englebrecht, I., Mastey, V., et al. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(01)80453-3 · Cited by 8
Drug treatment of Alzheimer's disease and responders to rivastigmine beyond 12 weeks
McMillan, H. (1999) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(199912)14:12<1078::aid-gps73>3.0.co;2-s · Cited by 5
Rivastigmine was effective and safe in Alzheimer disease
Wilkinson, D. G. (1999) · ACP Journal Club · doi:10.7326/acpjc-1999-131-2-034 · Cited by 5
529. Pharmacokinetics of rivastigmine and its metabolite in patients with Alzheimer’s disease
Cutler, N. R., Hossain, M., McDonald, C., Pommier, F., Sedek, G., Jhee, S. S., & Sramek, J. J. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00799-x · Cited by 4
Research works printed but not linked: 38
- Anand, 1996, Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's Disease: an overview, J Drug Dev Clin Pract, 8, 109
- Anand, 1996, Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's Disease: an overview, J Drug Dev Clin Pract, 8, 109
- Anand, 1996, Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's disease: an overview, J Drug Dev Clin Pract, 8, 109
- Cutler, 1995, Safety and tolerance of ENA 713 in patients with alzheimer's disease, Biological Psychiatry, 37, 643
- Anand, 2001, Effects of Alzheimer's disease severity on activities of daily living with long-term rivastigmine treatment, Journal of the American Geriatrics Society, 49, S151
- Hebert, 1999, [Alzheimer disease: efficacy and tolerance of rivastigmine], Presse Medicale, 28, 1757
- Rösler M Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial [Erratum] British Medical Journal 2001 1456
- Rösler, 1997, A double-blind placebo controlled study of ENA 713 in Alzheimer's disease (DAT), Pharmacopsychiatry, 30, 212
- Rösler, 1998, Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease, Behavioural-Neurology, 11, 211, 10.1155/1999/168023 · DOI
- Burns, 2004, Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease, International Journal of Geriatric Psychiatry, 19, 243, 10.1002/gps.1058 · DOI
- Farlow, 2003, Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial, Archives of Neurology, 60, 843, 10.1001/archneur.60.6.843 · DOI
- Burns, 2004, Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease, International Journal of Geriatric Psychiatry, 19, 243, 10.1002/gps.1058 · DOI
- Doraiswamy, 2000, Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately-severe to severe AD, Clinical Neuropschological Assessment, 1, 12
- Doraiswamy, 2000, Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine, Clinical Neuropschological Assessment, 1, 14
- Farlow, 2003, Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial, Archives of Neurology, 60, 843, 10.1001/archneur.60.6.843 · DOI
- Farlow, 2001, Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression, Archives of Neurology, 58, 417, 10.1001/archneur.58.3.417 · DOI
- Krishnan, 1999, Rivastigmine slows stage specific global deterioration in Alzheimer's disease, Journal of the American Geriatrics Society, 47, S3
- Tai, 2000, The safety and efficacy of Exelon in Alzheimer's patients: A multicentre, randomized, 26-week study in Taiwan, International Journal of Neuropsychopharmacology, 3, S356
- Cummings, 2000, Abstract S79.002, Neurology, 54, A468
- Anon Double-blind trial will compare two anti-alzheimer's drugs Journal of Dementia Care 6
- Bullock, 2005, Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period, Current Medical Research and Opinion, 21, 1317, 10.1185/030079905X56565 · DOI · Paper page
- Bullock, 2002, Rationale and design of EXCEED, a 24-month, double-blind study comparing rivastigmine and donepezil, Annals of Neurology, 52, 30
- Malsch, 2001, [Treatment of Alzheimer's disease: Tolerability of rivastigmine during the initial period], Psycho, 27, 337
- Wang, 2001, The treatment by using rivastigmine for patients with alzheimer disease: results of a multicenter, randomized, open-labeled, controlled clinical trial, Chinese Journal of Neurology, 34, 210
- Wang, 2003, [Efficacy of rivastigmine in treating mild to severe alzheimer's disease with different hachinski ischemia index], Chinese Journal of Neurology, 36, 44
- Bullock, 2001, The tolerability, ease of use and efficacy of donepezil and rivastigmine in Alzheimer's disease patients: a 12-week, multinational, comparative study, Journal of the American Geriatrics Society, 49, S19
- Benton, 1974, Revised visual retention test
- Brunner, 1990, Eine Validierungsstudie mit der NOSGER (Nurses' Observation Scale for Geriatric Patients), einem neuen Beurteilungsinstrument für die Psychogeriatrie, Zeitschr für Psychologie, XIX, 211
- Burns, 2004, Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease, International Journal of Geriatric Psychiatry, 19, 243, 10.1002/gps.1058 · DOI
- Cohen-Mansfield, 1995, Assessment of disruptive behaviour/agitation in the elderly: function, methods and difficulties, Journal of Geriatric Psychiatry Neurology, 8, 52
- 1994, Diagnostic and Statistical Manual of Mental Disorders
- Farlow, Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial, Archives of neurology, 60, 843, 10.1001/archneur.60.6.843 · DOI
- Grossberg, 2004, Erratum, American Journal of Geriatric Psychiatry, 12, 679, 10.1097/00019442-200411000-00016 · doi:10.1097/00019442-200411000-00016
- Guy, 1976, .,, 1976
- Kaufer, 2004, Consistent Long-term Efficacy of Rivastigmine in Mild, Moderate and Moderately Severe Alzheimer's Disease, NeuroBiology of Aging, 25, 101, 10.1016/S0197-4580(04)80340-3 · doi:10.1016/s0197-4580(04)80340-3
- Reisberg, 1994, CIBIC-plus interview guide
- Schneider, 1998, Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease, International Journal of Geriatric Psychopharmacology, 1, S26
- Wechsler, 1987, Wechsler Memory Scale-Revised (WMS-R)
Cited by
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789
Acetylcholinesterase Inhibitors: Pharmacology and Toxicology
Colovic, M. B., Krstic, D. Z., Lazarevic-Pasti, T. D., Bondzic, A. M., & Vasic, V. M. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311030006 · Cited by 2,611
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
Metadata
- Authors
- Birks, J., Grimley Evans, J., Iakovidou, V., & Tsolaki, M.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2009-04-15
- Issue
- 2
- Pages
- CD001191-CD001191
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W4211075001
- Cited by
- 296
- References
- 82
- Type
- reference entry
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.